Skip to main content
Top
Published in: Journal of General Internal Medicine 8/2015

01-08-2015 | Editorial

Overdoses in Patients on Opioids: Risks Associated with Mental Health Conditions and Their Treatment

Authors: Matthew J. Bair, MD, MS, Amy S. Bohnert, PhD, MHS

Published in: Journal of General Internal Medicine | Issue 8/2015

Login to get access

Excerpt

For more than 20 years, opioid therapy has expanded beyond cancer pain treatment to widespread use for various chronic pain conditions. While opioids have improved the quality of life for many patients disabled by chronic pain, their long-term use remains controversial for several reasons. First, the long-term efficacy of opioids is unclear. Opioids provide clinically significant relief for only a minority of patients1—many patients continue to experience severe, disabling pain despite opioid treatment. Second, opioids are associated with several problematic side effects that many patients report as intolerable. In addition, opioids may lead to adverse physiologic effects (e.g., hyperalgesia and hypogonadism) not necessarily reversed by stopping opioid therapy. Third, opioids have potential for misuse, which may occur more frequently than previously thought. Although physical dependence is an expected result of chronic opioid use, some patients develop an opioid use disorder. Fourth and most concerning, is that with the wider use of opioids, there has been a parallel increase in opioid-related overdose deaths. Between 1999 and 2009, the rate of prescription opioid overdose deaths in the U.S. rose fourfold,2 reflecting an epidemic of prescription opioid overdoses. …
Literature
1.
go back to reference Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–80.PubMedCrossRef Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–80.PubMedCrossRef
2.
go back to reference Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2009. Drug Alcohol Depend. 2013;131(3):263–70.PubMedCentralPubMedCrossRef Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2009. Drug Alcohol Depend. 2013;131(3):263–70.PubMedCentralPubMedCrossRef
3.
go back to reference Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–21.PubMedCrossRef Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–21.PubMedCrossRef
5.
go back to reference Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686–91.PubMedCrossRef Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686–91.PubMedCrossRef
6.
go back to reference Franklin GM, Mai J, Turner J, Sullivan M, Wickizer T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012;55(4):325–31.PubMedCrossRef Franklin GM, Mai J, Turner J, Sullivan M, Wickizer T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012;55(4):325–31.PubMedCrossRef
7.
go back to reference Turner BJ, Liang Y. Drug overdose in a retrospective cohort with non-cancer pain treated with opioids, antidepressants, and/or sedative-hypnotics: interactions with mental health disorders. J Gen Intern Med. 2015, [SPI 3199]. Turner BJ, Liang Y. Drug overdose in a retrospective cohort with non-cancer pain treated with opioids, antidepressants, and/or sedative-hypnotics: interactions with mental health disorders. J Gen Intern Med. 2015, [SPI 3199].
8.
go back to reference Bohnert AS, Ilgen MA, Ignacio RV, McCarthy JF, Valenstein M, Blow FC. Risk of death from accidental overdose associated with psychiatric and substance use disorders. Am J Psychiatry. 2012;169:64–70.PubMedCrossRef Bohnert AS, Ilgen MA, Ignacio RV, McCarthy JF, Valenstein M, Blow FC. Risk of death from accidental overdose associated with psychiatric and substance use disorders. Am J Psychiatry. 2012;169:64–70.PubMedCrossRef
9.
go back to reference Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain co-morbidity: a literature review. Arch Intern Med. 2003;163:2433–45.PubMedCrossRef Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain co-morbidity: a literature review. Arch Intern Med. 2003;163:2433–45.PubMedCrossRef
10.
go back to reference Miller M, Barber CW, Leatherman S, Fonda J, Hermos JA, Cho K, Gagnon DR. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015. doi:10.1001/jamainternmed.2014.8071. Miller M, Barber CW, Leatherman S, Fonda J, Hermos JA, Cho K, Gagnon DR. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015. doi:10.​1001/​jamainternmed.​2014.​8071.
Metadata
Title
Overdoses in Patients on Opioids: Risks Associated with Mental Health Conditions and Their Treatment
Authors
Matthew J. Bair, MD, MS
Amy S. Bohnert, PhD, MHS
Publication date
01-08-2015
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 8/2015
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3332-4

Other articles of this Issue 8/2015

Journal of General Internal Medicine 8/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine